Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Invitrx Therapeutics, Inc.
WARNING LETTER
•Invitrx Therapeutics, Inc.•March 22, 2022

Invitrx Therapeutics, Inc. – FDA Warning Letter, Mar 22, 2022

Record Details

The FDA issued a Warning Letter to Invitrx Therapeutics, Inc. on November 9, 2022, following an inspection from March 1-22, 2022. The inspection revealed that Invitrx manufactures and distributes unapproved cellular and exosome products (Invitra UC-MSC™, Invitra EX™, Invitra EV-OP™) for allogeneic use, intended to be sterile and treat various conditions. These products are classified as unapproved drugs and biological products under the FD&C Act and PHS Act, requiring a valid biologics license or an Investigational New Drug (IND) application, neither of which Invitrx possesses.

Specifically, Invitra UC-MSC™ fails to meet the homologous use and minimal manipulation criteria for HCT/Ps, subjecting it to drug and biologic regulations. The letter also highlights significant, repeat deviations from Current Good Manufacturing Practice (CGMP) and Current Good Tissue Practice (CGTP), including: * Failure to determine and document donor eligibility for hundreds of tissue donors. * Inadequate aseptic processing validation, including improper storage of sterile components and insufficient environmental monitoring. * Unvalidated in-house sterility testing methods and inadequate sample numbers. * Lack of validated manufacturing processes and appropriate product specifications. * Failure to test components and closures before use. * Absence of stability data to support assigned expiration dates. * Failure to investigate product complaints, including adverse events

Company
Invitrx Therapeutics, Inc.
Inspection date
March 22, 2022
Product type
Biologics
Office
Division of Biological Products Operations II
Person
  • Karlton T. Watson (Program Division Director)
View Company Profile

ID · 460f9034-1524-4320-84f4-f6f2f034a687

Violation Codes10
21 U.S.C. 321(g)21 U.S.C. 355(i)21 CFR 1271.3(d)21 CFR 127142 U.S.C. 262(a)(3)21 CFR 31242 U.S.C. 262(a)21 CFR 1271.50(a)21 CFR 1271.10(a)(2)21 CFR 1271.10(a)(1)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Invitrx Therapeutics, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.